We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seem to do the same last Friday if I remember then fell Monday - traders looking for 0.1% lol
Steady buying today by the looks of it. Hope this translates into a higher sp!!
GLA
I have been writing an article very recently ( not published as yet) On the NHS This is an aside But clearly Dosing Regimes such as this are not only excellent news for patients but also present significant costs savings too. Drug mis-use primarily over ordering and not using cost The NHS millions each year, potential savings are enormous. So too the use of Generic Drugs which worldwide currently cost Health Service providers in excess of £400 billion a year and projected to rise to over £600 billion by 2030. The NHS has been intransigent but needs to avail itself of all the emergent technologies that diagnostic medical techniques present. As a complete aside We should also have a Government funded Generic GMP facility in the UK The savings would more than warrant its building and operation instead of making some foreign manufacturers incredibly wealthy!
Peter promosed more events as this is increasingly important for new business
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunities. A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings
I would also like to second Trench’s Post.
Ant your contribution are brilliant and very much welcomed.
I have been invested in PYC for many many many years and the personalised dosing tool as stated numerous times could / should have huge commercial value.
I could be wrong but my understanding although there is numerous way it could be rolled out if approved that the technology would be integrated to Dosemerx and PYC would get a fee for this tech per license of which DoseMe has hundreds of thousand licenses in hospitals, surgery’s, universities and practises world wide !!!
This in mind the potential is exponential before you look at the UK (NHS) and European market
Difficult to buy today?
Ant, thanks for your excellent contributions which are most interesting and welcome
PYC have been banging the drum for personalised medicine for many years. They should be well placed to take full advantage now that the industry has finally recognised its huge potential opportunities and benefits
Https://invst.ly/14gktm
poss reversal in play upper trend line to break,buy volume to endorse
Trench around 25 years ago Oxford University presented a personalised dosing mechanism to The Royal Society it was primarily designed to be for Diabetes Patients and intended to rely on a Grid they were developing as a secure alternative to "the internet" It was being designed to pass information and control from and to patients. My recollections are scanty save that it attracted offers of serious finance to progress and whilst afforded my offer of funding at the time was frozen out. The availability of Cloud based technology now only serves to enhance this concept. It is this type of "add on" that could really accelerate the take up of DoseMeRX . On the evidence of past experience and as above, there will be significant monies made available by Pharma Cos worldwide as they are all keen to accurately deliver correct dosing regimes on a personalised basis . It may well prove to be the gamechanger here we are all predicting. The time is now right as unlike previously, while a number of us were engaged in thoughts of Personalised medicines then it was a step to far. I don't need to wish shareholders good luck the technology that PYC have at their disposal will provide the answers!
Also attending this next week.
https://www.physiomics.co.uk/biotrinity-2024/
Physiomics attending next week.
https://www.physiomics.co.uk/oxford-global-immuno-2024/
Correct De Bull - its was founded and started in Australia.
Doseme was acquired by Tabula Rasa Health Care for £20 Million Dollars
Tabula Rasa then got rid of the assets as it wasn't a core one and wasn't generating any cash - they eventually sold this for £1.5 Million making a significant Multi million lost
Trench, did they not start off in Oz and have a office there to?
DoseMeRx is a game-changing solution that enables customers to accelerate their precision dosing strategies with superior analytics and reporting. The guideposts of DoseMe’s ongoing investment are to improve overall clinical expertise and valuable clinical decision support to assist customers in offering the highest quality patient care.
This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe’s commitment to global expansion and continuous innovation to deliver advanced precision dosing.
Excellent news Trench
DosemeRx have posted this which suggests they have strong growth ambitions and would be an excellent partner if PYC are able to strike a commercial deal with them
https://doseme-rx.com/news-media/article/doseme-expands-global-footprint-in-australia
On a recent IMC presentation JM mentioned that 'at the point when we mutually decide that we want to move to a commercial phase that will be quite quick because Doseme clients use the tool on a Cloud-based system and it doesn't require a complicated and lengthy roll-out'
I'm a LTH Laura. Bought more last week...
GLA
I was a bit unsure when the company announced that it was initiating a company newsletter
However, I have been impressed by how much relevant news has been contained in the first few issues. It is a credit to the determined effort PYC are making to improve the profile of the company. Lets hope this continues in the near term with details regarding the Head of Modelling appointment, maybe an update on the G-CSF project, some important news on the Biostatistics initiative, contract announcements etc. Exciting times for those with a genuine interest
This person is very odd
Click on their posting summaries, every day if every week they post the same drivel on 100s of shares
Prostate cancer and "cell dormancy "
Dr Green said the funding, of £2.34m from The Wellcome Trust and £500,000 from Yorkshire Cancer Research, would "bring together international experts to gain a deeper understanding of cancer cell dormancy in myeloma".
"By better understanding the cells, this research can either make Karonudib more effective, or may help generate completely new treatments," she said.
She said the additional money from Yorkshire Cancer Research would also fund research into cell dormancy in cancers that spread to bone, like breast and prostate cancer.
Brilliant news..thanks Ralph
Pyc announced contract with Sheffield Uni etc in February, BBC announced following.
More than £2.5m will be ploughed into new research into blood cancer in Sheffield, it has been announced.
The University of Sheffield was given the funding to look into dormant cancer cells and develop new treatments for myeloma, a type of blood cancer.
https://x.com/physiomics/status/1780186840005259327?s=61&t=0G9XeE3tHfuoBf1VEsPycQ
Still maximum buy of 200,000 shares (£2500)
Been like this for 5 + days now ?
Clear to see that the "traders" like Hopist didn't last long
77k and 96k sells today were bought on Friday
Glad they're out to be honest...
Debull
There has been low interest cross WHOLE of AIM last 18mths not just PYC
Also all PYC can do is keep on increasing client base and revenues..which they are doing..Peter looks like the person to drive this even further